Serum homocysteine and asymmetric dimethylarginine levels in patients with premature ovarian failure: a prospective controlled study

Objective. Objective. To investigate serum homocysteine and asymmetric dimethylarginine (ADMA) levels in patients with premature ovarian failure (POF). Study design. A total of 69 women, 32 with POF and 37 apparently healthy women were included in the study. Fasting blood samples were drawn to measure serum homocysteine and ADMA levels using ELISA method. Results. The study and control group had a mean age of 37.3 + 2.6, 37.5 + 2.5 years; a mean homocysteine level of 13.54 + 5.19, 12.71 + 3.99 mmol/l and a mean ADMA level of 1.32 + 0.27, 1.26 + 0.36 mmol/l, respectively. There were no statistically significant differences between the two groups in terms of homocysteine and ADMA levels (with p values of 0.465 and 0.423, respectively). A negative significant correlation was found between estradiol and ADMA (p <0.05). Conclusion. Homocysteine and ADMA levels did not change in comparison with the control group, which suggests that estrogen deficiency in patients with POF does not have any effect on homocysteine and asymmetric dimethylarginine levels.

[1]  A. LaCroix,et al.  Homocysteine levels and risk of hip fracture in postmenopausal women. , 2009, The Journal of clinical endocrinology and metabolism.

[2]  P. Scheffer,et al.  The influence of physiological and surgical menopause on coronary heart disease risk markers , 2009, Menopause.

[3]  N. Panay,et al.  Spontaneous premature ovarian failure: Management challenges , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[4]  G. Kurtay,et al.  A comparison of the effects of sequential transdermal versus continuous orally administered hormone replacement therapies on plasma total homocysteine levels in postmenopausal women: a randomized, placebo-controlled study. , 2007, European journal of obstetrics, gynecology, and reproductive biology.

[5]  T. Yurdun,et al.  Plasma markers of NO synthase activity in women after ovarian hyperstimulation: influence of estradiol on ADMA , 2006, Vascular medicine.

[6]  P. Crosignani,et al.  Age, menopausal status and homocysteine levels in women around menopause. , 2005, European journal of obstetrics, gynecology, and reproductive biology.

[7]  O. Stanger,et al.  Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. , 2005, Current drug metabolism.

[8]  L. Mosekilde,et al.  A Common Methylenetetrahydrofolate Reductase (C677T) Polymorphism Is Associated With Low Bone Mineral Density and Increased Fracture Incidence After Menopause: Longitudinal Data From the Danish Osteoporosis Prevention Study , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  P. Mills,et al.  Effects of estrogen and psychological stress on plasma homocysteine levels. , 2003, Fertility and sterility.

[10]  B. Abrahamsen,et al.  Association of a Common Allelic Polymorphism (C677T) in the Methylene Tetrahydrofolate Reductase Gene with a Reduced Risk of Osteoporotic Fractures. A Case Control Study in Danish Postmenopausal Women , 2002, Calcified Tissue International.

[11]  S. Kristensen,et al.  Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. , 2002, American journal of obstetrics and gynecology.

[12]  U. Turpeinen,et al.  Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. , 2000, Fertility and sterility.

[13]  A. Hofman,et al.  Increased plasma homocysteine after menopause. , 2000, Atherosclerosis.

[14]  Y. Ouchi,et al.  Association of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphism with Bone Mineral Density in Postmenopausal Japanese Women , 2000, Calcified Tissue International.

[15]  C. W. Prince,et al.  Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging. , 2000, The Journal of nutrition.

[16]  G. Boers,et al.  Homocysteine, vitamin status and risk of vascular disease; effects of gender and menopausal status. European COMAC Group. , 1999, European heart journal.

[17]  W. M. van Baal,et al.  A Randomized Controlled Study of the Effects of 17Beta‐Estradiol‐Dydrogesterone on Plasma Homocysteine in Postmenopausal Women , 1998, Obstetrics and gynecology.

[18]  S. Vollset,et al.  Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.

[19]  K. Woo,et al.  Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. , 1997, Circulation.

[20]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[21]  H. Blom,et al.  The effect of sequential three‐monthly hormone replacement therapy on several cardiovascular risk estimators in post‐menopausal women , 1997, Fertility and sterility.

[22]  M. Creager,et al.  Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. , 1997, Circulation.

[23]  C. Sobey,et al.  Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.

[24]  S. Vollset,et al.  Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. , 1995, JAMA.

[25]  H. Blom,et al.  Plasma homocysteine and menopausal status ** , 1995, European journal of clinical investigation.

[26]  M. Secic,et al.  Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. , 1994, Clinical chemistry.

[27]  P. Wilson,et al.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. , 1993, JAMA.

[28]  A. Isaksson,et al.  Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status , 1992, European journal of clinical investigation.

[29]  J. Hardebo,et al.  Folic acid responsive postmenopausal homocysteinemia. , 1985, Metabolism: clinical and experimental.

[30]  G. Boers,et al.  Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. , 1983, The Journal of clinical investigation.

[31]  G. Rodrigues de Lima,et al.  Effects of estrogen and estrogen-progestogen therapy on homocysteine levels and their correlation with carotid vascular resistance. , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[32]  Xiang Li,et al.  Effect of endogenous estrogen on endothelial function in women with coronary heart disease and its mechanism. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[33]  D. Tsikas,et al.  ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. , 2003, Cardiovascular research.

[34]  E. Falk,et al.  Homocysteine and atherothrombosis , 2001, Lipids.